Mark G Lebwohl1, Hervé Bachelez2, Jonathan Barker3, Giampiero Girolomoni4, Arthur Kavanaugh5, Richard G Langley6, Carle F Paul7, Lluís Puig8, Kristian Reich9, Peter C M van de Kerkhof10. 1. The Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: mark.lebwohl@mountsinai.org. 2. Sorbonne Paris Cité Univ Paris Diderot, Department of Dermatology, APHP Saint-Louis Hospital, Paris, France. 3. St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College, London, United Kingdom. 4. University of Verona, Verona, Italy. 5. University of California, San Diego School of Medicine, La Jolla, California. 6. Dalhousie University, Halifax, Nova Scotia, Canada. 7. Department of Dermatology, Toulouse University and Larrey Hospital, Toulouse, France. 8. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 9. Sclderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany. 10. Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Abstract
BACKGROUND: Available psoriasis surveys offer valuable information about psoriasis and psoriatic arthritis (PsA), but are limited by methodology or enrollment requirements. OBJECTIVE: To further the understanding of the unmet needs of psoriasis and PsA patients. METHODS: This was a large, multinational, population-based survey of psoriasis and/or PsA patients in North America and Europe. Patients were selected by list-assisted random digit dialing and did not have to currently be under the care of a health care provider, a patient organization member, or receiving treatment; 139,948 households were screened and 3426 patients completed the survey. RESULTS: The prevalence of psoriasis/PsA ranged from 1.4% to 3.3%; 79% had psoriasis alone and 21% had PsA. When rating disease severity at its worst, 27% (psoriasis) and 53% (PsA ± psoriasis) of patients rated it as severe. Psoriasis patients indicated that their most bothersome signs or symptoms were itching (43%), scales (23%), and flaking (20%). Of psoriasis patients, 45% had not seen a physician in a year; >80% of psoriasis patients with ≥ 4 palms body surface area and 59% of PsA patients were receiving no treatment or topical treatment only. Of patients who had received oral or biologic therapy, 57% and 45%, respectively, discontinued therapy, most often for safety/tolerability reasons and a lack/loss of efficacy. LIMITATIONS: The survey lacked a control group, did not account for ethnic and health care system differences across countries, and was limited by factors associated with any patient survey, including accurate recall and interpretation of questions. CONCLUSIONS: Several identified unmet needs warrant additional attention and action, including improved severity assessment, PsA screening, patient awareness, and treatment options.
BACKGROUND: Available psoriasis surveys offer valuable information about psoriasis and psoriatic arthritis (PsA), but are limited by methodology or enrollment requirements. OBJECTIVE: To further the understanding of the unmet needs of psoriasis and PsA patients. METHODS: This was a large, multinational, population-based survey of psoriasis and/or PsA patients in North America and Europe. Patients were selected by list-assisted random digit dialing and did not have to currently be under the care of a health care provider, a patient organization member, or receiving treatment; 139,948 households were screened and 3426 patients completed the survey. RESULTS: The prevalence of psoriasis/PsA ranged from 1.4% to 3.3%; 79% had psoriasis alone and 21% had PsA. When rating disease severity at its worst, 27% (psoriasis) and 53% (PsA ± psoriasis) of patients rated it as severe. Psoriasispatients indicated that their most bothersome signs or symptoms were itching (43%), scales (23%), and flaking (20%). Of psoriasispatients, 45% had not seen a physician in a year; >80% of psoriasispatients with ≥ 4 palms body surface area and 59% of PsA patients were receiving no treatment or topical treatment only. Of patients who had received oral or biologic therapy, 57% and 45%, respectively, discontinued therapy, most often for safety/tolerability reasons and a lack/loss of efficacy. LIMITATIONS: The survey lacked a control group, did not account for ethnic and health care system differences across countries, and was limited by factors associated with any patient survey, including accurate recall and interpretation of questions. CONCLUSIONS: Several identified unmet needs warrant additional attention and action, including improved severity assessment, PsA screening, patient awareness, and treatment options.
Authors: Ennio Lubrano; Andrea Delle Sedie; Marco Romanelli; Maria Sole Chimenti; Luca Bianchi; Stefano Piaserico; Catia De Felice; Dario Graceffa; Maria Ilenia De Andres; Salvatore Curatolo; Rosa Daniela Grembiale; Stefano Dastoli; Chiara Arcuri; Rosa Giuseppa Angileri; Francesca Prignano; Francesca Bandinelli; Elena Baldissera; Santo Raffaele Mercuri; Chiara Franchi; Matteo Longhi; Angela Patrì; Francesco Caso; Giuseppe Passiu; Maria Antonia Montesu; Simone Parisi; Elena Stroppiana; Genoveffa Scotto di Luzio; Giovanni Italiano; Sergio Di Nuzzo; Daniele Santilli; Laura Bigi; Federica Lumetti; Concetto Paolo Agnusdei; Maria Grazia Ferrucci; Giuliana Gualberti; Francesca Marando; Roberta Ramonda; Francesco Cusano Journal: Clin Rheumatol Date: 2020-11-06 Impact factor: 2.980